New drug targets tough KRAS cancers in early trial
Disease control
Recruiting now
This study tests a new drug called WEF-001 in about 110 adults with advanced solid tumors (pancreatic, colorectal, lung, ovarian, bile duct, or bladder cancer) that have a KRAS gene mutation and have stopped responding to standard treatments. The goal is to check the drug's safet…
Phase: PHASE1, PHASE2 • Sponsor: Auricula Biosciences Inc. • Aim: Disease control
Last updated May 01, 2026 16:00 UTC